Lipid Regulation of the ABCB1 and ABCG2 Multidrug Transporters

Advances in Cancer Research

Volumn 125, Issue , 2015, Pages 97-137

  Hegedüs, Csilla ^a   Telbisz, Ágnes ^a   Hegedus, Tamás ^b   Sarkadi, Balázs ^a,b   Özvegy Laczka, Csilla ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

ABC multidrug transporter; Cholesterol; Membrane lipids; Nuclear receptors

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CELL NUCLEUS RECEPTOR; DETERGENT; MEMBRANE LIPID; MULTIDRUG RESISTANCE PROTEIN 1; TRANSCRIPTION FACTOR; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; CELL RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; TUMOR PROTEIN;

ARTICLE; COMPUTER MODEL; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; BIOSYNTHESIS; CELL MEMBRANE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LIPID METABOLISM; METABOLISM; MULTIDRUG RESISTANCE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TRANSPORT AT THE CELLULAR LEVEL;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; MEMBRANE LIPIDS; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; P-GLYCOPROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION, GENETIC;

EID: 84921836113     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2014.10.004     Document Type: Chapter

References (143)

1. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
2. Ambudkar S.V. Purification and reconstitution of functional human P-glycoprotein. Journal of Bioenergetics and Biomembranes 1995, 27:23-29.
3. Bacso Z., Nagy H., Goda K., Bene L., Fenyvesi F., Matko J., et al. Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry. Part A: The Journal of the International Society for Analytical Cytology 2004, 61:105-116.
4. Baier C.J., Fantini J., Barrantes F.J. Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor. Scientific Reports 2011, 1:69.
5. Beck A., Aanismaa P., Li-Blatter X., Dawson R., Locher K., Seelig A. Sav 1866 from Staphylococcus aureus and P-glycoprotein: Similarities and differences in ATPase activity assessed with detergents as allocrites. Biochemistry 2013, 52:3297-3309.
6. Belli S., Elsener P.M., Wunderli-Allenspach H., Kramer S.D. Cholesterol-mediated activation of P-glycoprotein: Distinct effects on basal and drug-induced ATPase activities. Journal of Pharmaceutical Sciences 2009, 98:1905-1918.
7. Benoki S., Yoshinari K., Chikada T., Imai J., Yamazoe Y. Transactivation of ABCG2 through a novel cis-element in the distal promoter by constitutive androstane receptor but not pregnane X receptor in human hepatocytes. Archives of Biochemistry and Biophysics 2012, 517:123-130.
8. Beyea M.M., Heslop C.L., Sawyez C.G., Edwards J.Y., Markle J.G., Hegele R.A., et al. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. The Journal of Biological Chemistry 2007, 282:5207-5216.
9. Bhatia A., Schafer H.J., Hrycyna C.A. Oligomerization of the human ABC transporter ABCG2: Evaluation of the native protein and chimeric dimers. Biochemistry 2005, 44:10893-10904.
10. Blazquez A.G., Briz O., Romero M.R., Rosales R., Monte M.J., Vaquero J., et al. Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Molecular Pharmacology 2012, 81:273-283.
11. Borst P., Elferink R.O. Mammalian ABC transporters in health and disease. Annual Review of Biochemistry 2002, 71:537-592.
12. Bosch I., Dunussi-Joannopoulos K., Wu R.L., Furlong S.T., Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 1997, 36:5685-5694.
13. Bucher K., Belli S., Wunderli-Allenspach H., Kramer S.D. P-glycoprotein in proteoliposomes with low residual detergent: The effects of cholesterol. Pharmaceutical Research 2007, 24:1993-2004.
14. Bucher K., Besse C.A., Kamau S.W., Wunderli-Allenspach H., Kramer S.D. Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities. Pharmaceutical Research 2005, 22:449-457.
15. Burk O., Arnold K.A., Geick A., Tegude H., Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biological Chemistry 2005, 386:503-513.
16. Cerveny L., Svecova L., Anzenbacherova E., Vrzal R., Staud F., Dvorak Z., et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2007, 35:1032-1041.
17. Chan G.N., Hoque M.T., Bendayan R. Role of nuclear receptors in the regulation of drug transporters in the brain. Trends in Pharmacological Sciences 2013, 34:361-372.
18. Chan G.N., Hoque M.T., Cummins C.L., Bendayan R. Regulation of P-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. Journal of Neurochemistry 2011, 118:163-175.
19. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: Opening the X-files. Science 2001, 294:1866-1870.
20. Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.Q., Sugimoto Y., et al. Transport of methotrexate, methotrexate polyglutamates, and 17 beta-estradiol 17-(beta-d-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. Cancer Research 2003, 63:4048-4054.
21. Chisaki I., Kobayashi M., Itagaki S., Hirano T., Iseki K. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver. Biochimica et Biophysica Acta 2009, 1788:2396-2403.
22. Clay A.T., Sharom F.J. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. Biochemistry 2013, 52:343-354.
23. Coleman J.A., Quazi F., Molday R.S. Mammalian P4-ATPases and ABC transporters and their role in phospholipid transport. Biochimica et Biophysica Acta 2013, 1831:555-574.
24. Decottignies A., Kolaczkowski M., Balzi E., Goffeau A. Solubilization and characterization of the overexpressed PDR5 multidrug resistance nucleotide triphosphatase of yeast. The Journal of Biological Chemistry 1994, 269:12797-12803.
25. Denning E.J., Beckstein O. Influence of lipids on protein-mediated transmembrane transport. Chemistry and Physics of Lipids 2013, 169:57-71.
26. De Rosa M.F., Ackerley C., Wang B., Ito S., Clarke D.M., Lingwood C. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. The Journal of Biological Chemistry 2008, 283:4501-4511.
27. Ding F., Buldyrev S.V., Dokholyan N.V. Folding Trp-cage to NMR resolution native structure using a coarse-grained protein model. Biophysical Journal 2005, 88:147-155.
28. Doige C.A., Yu X., Sharom F.J. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochimica et Biophysica Acta 1993, 1146:65-72.
29. Eckford P.D., Sharom F.J. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. The Biochemical Journal 2005, 389:517-526.
30. Ee P.L., Kamalakaran S., Tonetti D., He X., Ross D.D., Beck W.T. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Research 2004, 64:1247-1251.
31. Epand R.M. Cholesterol and the interaction of proteins with membrane domains. Progress in Lipid Research 2006, 45:279-294.
32. Evans R.M. The nuclear receptor superfamily: A rosetta stone for physiology. Molecular Endocrinology 2005, 19:1429-1438.
33. Evans R.M., Mangelsdorf D.J. Nuclear receptors, RXR, and the Big Bang. Cell 2014, 157:255-266.
34. Gál Z., Hegedüs C., Szakács G., Váradi A., Sarkadi B., Özvegy-Laczka C. utations of the central tyrosines of putative Cholesterol Recognition Amino acid Consensus (CRAC) sequences modify folding, activity, and steroid-sensing of the human ABCG2 multidrug transporter. BBA Biomembranes 2014, in press.
35. Geick A., Eichelbaum M., Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. The Journal of Biological Chemistry 2001, 276:14581-14587.
36. Globisch C., Pajeva I.K., Wiese M. Identification of putative binding sites of P-glycoprotein based on its homology model. ChemMedChem 2008, 3:280-295.
37. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nature Reviews. Drug Discovery 2004, 3:950-964.
38. Handschin C., Meyer U.A. Regulatory network of lipid-sensing nuclear receptors: Roles for CAR, PXR, LXR, and FXR. Archives of Biochemistry and Biophysics 2005, 433:387-396.
39. Hazai E., Bikadi Z. Homology modeling of breast cancer resistance protein (ABCG2). Journal of Structural Biology 2008, 162:63-74.
40. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase?. Trends in Biochemical Sciences 1992, 17:18-21.
41. Hinrichs J.W., Klappe K., Kok J.W. Rafts as missing link between multidrug resistance and sphingolipid metabolism. The Journal of Membrane Biology 2005, 203:57-64.
42. Hollo Z., Homolya L., Davis C.W., Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochimica et Biophysica Acta 1994, 1191:384-388.
43. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. The Journal of Biological Chemistry 1993, 268:21493-21496.
44. Homolya L., Hollo M., Muller M., Mechetner E.B., Sarkadi B. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. British Journal of Cancer 1996, 73:849-855.
45. Homolya L., Orban T.I., Csanady L., Sarkadi B. Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. Biochimica et Biophysica Acta 2011, 1808:154-163.
46. Honjo Y., Hrycyna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van de Laar A., et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Research 2001, 61:6635-6639.
47. Hoque M.T., Robillard K.R., Bendayan R. Regulation of breast cancer resistant protein by peroxisome proliferator-activated receptor alpha in human brain microvessel endothelial cells. Molecular Pharmacology 2012, 81:598-609.
48. Im Y.J., Raychaudhuri S., Prinz W.A., Hurley J.H. Structural mechanism for sterol sensing and transport by OSBP-related proteins. Nature 2005, 437:154-158.
49. Ismair M.G., Hausler S., Stuermer C.A., Guyot C., Meier P.J., Roth J., et al. ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes. Hepatology 2009, 49:1673-1682.
50. Janvilisri T., Shahi S., Venter H., Balakrishnan L., van Veen H.W. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). The Biochemical Journal 2005, 385:419-426.
51. Jigorel E., Le Vee M., Boursier-Neyret C., Parmentier Y., Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:1756-1763.
52. Jin M.S., Oldham M.L., Zhang Q., Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012, 490:566-569.
53. Jonker J.W., Stedman C.A., Liddle C., Downes M. Hepatobiliary ABC transporters: Physiology, regulation and implications for disease. Frontiers in Bioscience (Landmark Edition) 2009, 14:4904-4920.
54. Kim W.Y., Benet L.Z. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharmaceutical Research 2004, 21:1284-1293.
55. Kimura Y., Kioka N., Kato H., Matsuo M., Ueda K. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. The Biochemical Journal 2007, 401:597-605.
56. Kimura Y., Kodan A., Matsuo M., Ueda K. Cholesterol fill-in model: Mechanism for substrate recognition by ABC proteins. Journal of Bioenergetics and Biomembranes 2007, 39:447-452.
57. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacological Reviews 2010, 62:1-96.
58. Klein M.L., Shinoda W. Large-scale molecular dynamics simulations of self-assembling systems. Science 2008, 321:798-800.
59. Kurose K., Saeki M., Tohkin M., Hasegawa R. Thyroid hormone receptor mediates human MDR1 gene expression-Identification of the response region essential for gene expression. Archives of Biochemistry and Biophysics 2008, 474:82-90.
60. Laganowsky A., Reading E., Allison T.M., Ulmschneider M.B., Degiacomi M.T., Baldwin A.J., et al. Membrane proteins bind lipids selectively to modulate their structure and function. Nature 2014, 510:172-175.
61. Li Y.F., Polgar O., Okada M., Esser L., Bates S.E., Xia D. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: A molecular modeling study. Journal of Molecular Graphics & Modelling 2007, 25:837-851.
62. Li-Blatter X., Nervi P., Seelig A. Detergents as intrinsic P-glycoprotein substrates and inhibitors. Biochimica et Biophysica Acta 2009, 1788:2335-2344.
63. London E., Brown D.A. Insolubility of lipids in triton X-100: Physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochimica et Biophysica Acta 2000, 1508:182-195.
64. Loo T.W., Bartlett M.C., Clarke D.M. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. The Biochemical Journal 2006, 399:351-359.
65. Loo T.W., Bartlett M.C., Clarke D.M. Arginines in the first transmembrane segment promote maturation of a P-glycoprotein processing mutant by hydrogen bond interactions with tyrosines in transmembrane segment 11. The Journal of Biological Chemistry 2008, 283:24860-24870.
66. Loo T.W., Bartlett M.C., Clarke D.M. Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis. The Journal of Biological Chemistry 2009, 284:24074-24087.
67. Loo T.W., Clarke D.M. Drug rescue distinguishes between different structural models of human P-glycoprotein. Biochemistry 2013, 52:7167-7169.
68. Luker G.D., Pica C.M., Kumar A.S., Covey D.F., Piwnica-Worms D. Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry 2000, 39:7651-7661.
69. Maglich J.M., Stoltz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., Kliewer S.A. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular Pharmacology 2002, 62:638-646.
70. Mao Q., Deeley R.G., Cole S.P. Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. The Journal of Biological Chemistry 2000, 275:34166-34172.
71. Marcoux J., Wang S.C., Politis A., Reading E., Ma J., Biggin P.C., et al. Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:9704-9709.
72. Marrink S.J., Tieleman D.P. Perspective on the Martini model. Chemical Society Reviews 2013, 42:6801-6822.
73. Marsh D., Pali T. Orientation and conformation of lipids in crystals of transmembrane proteins. European Biophysics Journal : EBJ 2013, 42:119-146.
74. Mashiach E., Schneidman-Duhovny D., Andrusier N., Nussinov R., Wolfson H.J. FireDock: A web server for fast interaction refinement in molecular docking. Nucleic Acids Research 2008, 36:W229-W232.
75. Mayor S., Rao M. Rafts: Scale-dependent, active lipid organization at the cell surface. Traffic 2004, 5:231-240.
76. Mazzanti R., Fantappie O., Kamimoto Y., Gatmaitan Z., Gentilini P., Arias I.M. Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles. Hepatology 1994, 20:170-176.
77. Miwa M., Tsukahara S., Ishikawa E., Asada S., Imai Y., Sugimoto Y. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. International Journal of Cancer. Journal International Du Cancer 2003, 107:757-763.
78. Modok S., Heyward C., Callaghan R. P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment. Journal of Lipid Research 2004, 45:1910-1918.
79. Munro S. Lipid rafts: Elusive or illusive?. Cell 2003, 115:377-388.
80. Natarajan K., Xie Y., Baer M.R., Ross D.D. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochemical Pharmacology 2012, 83:1084-1103.
81. Ni Z., Mark M.E., Cai X., Mao Q. Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. International Journal of Biochemistry and Molecular Biology 2010, 1:1-11.
82. Ohvo-Rekila H., Ramstedt B., Leppimaki P., Slotte J.P. Cholesterol interactions with phospholipids in membranes. Progress in Lipid Research 2002, 41:66-97.
83. O'Mara M.L., Tieleman D.P. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav 1866 and MalK. FEBS Letters 2007, 581:4217-4222.
84. Orlowski S., Martin S., Escargueil A. P-glycoprotein and 'lipid rafts': Some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cellular and Molecular Life Sciences: CMLS 2006, 63:1038-1059.
85. Orlowski S., Selosse M.A., Boudon C., Micoud C., Mir L.M., Belehradek J., et al. Effects of detergents on P-glycoprotein atpase activity: Differences in perturbations of basal and verapamil-dependent activities. Cancer Biochemistry Biophysics 1998, 16:85-110.
86. Ory D.S. Nuclear receptor signaling in the control of cholesterol homeostasis: Have the orphans found a home?. Circulation Research 2004, 95:660-670.
87. Ozvegy C., Litman T., Szakacs G., Nagy Z., Bates S., Varadi A., et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochemical and Biophysical Research Communications 2001, 285:111-117.
88. Ozvegy C., Varadi A., Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. The Journal of Biological Chemistry 2002, 277:47980-47990.
89. Pajeva I.K., Globisch C., Wiese M. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein. The FEBS Journal 2009, 276:7016-7026.
90. Pal A., Mehn D., Molnar E., Gedey S., Meszaros P., Nagy T., et al. Cholesterol potentiates ABCG2 activity in a heterologous expression system: Improved in vitro model to study function of human ABCG2. The Journal of Pharmacology and Experimental Therapeutics 2007, 321:1085-1094.
91. Peetla C., Vijayaraghavalu S., Labhasetwar V. Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Advanced Drug Delivery Reviews 2013, 65:1686-1698.
92. Phillips R., Ursell T., Wiggins P., Sens P. Emerging roles for lipids in shaping membrane-protein function. Nature 2009, 459:379-385.
93. Pike L.J. Lipid rafts: Bringing order to chaos. Journal of Lipid Research 2003, 44:655-667.
94. Pohl A., Devaux P.F., Herrmann A. Function of prokaryotic and eukaryotic ABC proteins in lipid transport. Biochimica et Biophysica Acta 2005, 1733:29-52.
95. Radeva G., Perabo J., Sharom F.J. P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains. The FEBS Journal 2005, 272:4924-4937.
96. Raviv Y., Pollard H.B., Bruggemann E.P., Pastan I., Gottesman M.M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. The Journal of Biological Chemistry 1990, 265:3975-3980.
97. Romsicki Y., Sharom F.J. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 1999, 38:6887-6896.
98. Romsicki Y., Sharom F.J. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 2001, 40:6937-6947.
99. Rong X., Albert C.J., Hong C., Duerr M.A., Chamberlain B.T., Tarling E.J., et al. LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell Metabolism 2013, 18:685-697.
100. Rosenberg M.F., Bikadi Z., Chan J., Liu X., Ni Z., Cai X., et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 2010, 18:482-493.
101. Saeki M., Kurose K., Hasegawa R., Tohkin M. Functional analysis of genetic variations in the 5'-flanking region of the human MDR1 gene. Molecular Genetics and Metabolism 2011, 102:91-98.
102. Saeki M., Kurose K., Tohkin M., Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochemical Pharmacology 2008, 76:531-542.
103. Sarkadi B., Homolya L., Szakacs G., Varadi A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiological Reviews 2006, 86:1179-1236.
104. Sarkadi B., Muller M., Hollo Z. The multidrug transporters-proteins of an ancient immune system. Immunology Letters 1996, 54:215-219.
105. Schmidt M.R., Stansfeld P.J., Tucker S.J., Sansom M.S. Simulation-based prediction of phosphatidylinositol 4,5-bisphosphate binding to an ion channel. Biochemistry 2013, 52:279-281.
106. Schmitz G., Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochimica et Biophysica Acta 2005, 1735:1-19.
107. Schneidman-Duhovny D., Inbar Y., Nussinov R., Wolfson H.J. PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Research 2005, 33:W363-W367.
108. Schuck S., Honsho M., Ekroos K., Shevchenko A., Simons K. Resistance of cell membranes to different detergents. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5795-5800.
109. Scotto K.W. Transcriptional regulation of ABC drug transporters. Oncogene 2003, 22:7496-7511.
110. Seelig A., Gerebtzoff G. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opinion on Drug Metabolism & Toxicology 2006, 2:733-752.
111. Shapiro A.B., Ling V. Reconstitution of drug transport by purified P-glycoprotein. The Journal of Biological Chemistry 1995, 270:16167-16175.
112. Sharom F.J. The P-glycoprotein efflux pump: How does it transport drugs?. The Journal of Membrane Biology 1997, 160:161-175.
113. Sharom F.J. Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: Its role in modulating protein function. Frontiers in Oncology 2014, 4:41.
114. Sharom F.J., Yu X., Chu J.W., Doige C.A. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. The Biochemical Journal 1995, 308(Pt 2):381-390.
115. Sharom F.J., Yu X., Doige C.A. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. The Journal of Biological Chemistry 1993, 268:24197-24202.
116. Siarheyeva A., Lopez J.J., Glaubitz C. Localization of multidrug transporter substrates within model membranes. Biochemistry 2006, 45:6203-6211.
117. Simons K., Gerl M.J. Revitalizing membrane rafts: New tools and insights. Nature Reviews. Molecular Cell Biology 2010, 11:688-699.
118. Speelmans G., Staffhorst R.W., De Wolf F.A., De Kruijff B. Verapamil competes with doxorubicin for binding to anionic phospholipids resulting in increased internal concentrations and rates of passive transport of doxorubicin. Biochimica et Biophysica Acta 1995, 1238:137-146.
119. Storch C.H., Ehehalt R., Haefeli W.E., Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. The Journal of Pharmacology and Experimental Therapeutics 2007, 323:257-264.
120. Suzuki M., Suzuki H., Sugimoto Y., Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. The Journal of Biological Chemistry 2003, 278:22644-22649.
121. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Medicine 2001, 7:584-590.
122. Szatmari I., Vamosi G., Brazda P., Balint B.L., Benko S., Szeles L., et al. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. The Journal of Biological Chemistry 2006, 281:23812-23823.
123. Tarling E.J., de Aguiar Vallim T.Q., Edwards P.A. Role of ABC transporters in lipid transport and human disease. Trends in Endocrinology and Metabolism: TEM 2013, 24:342-350.
124. Telbisz A., Hegedus C., Varadi A., Sarkadi B., Ozvegy-Laczka C. Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: Effects of mutations in potential substrate and steroid binding sites. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2014, 42:575-585.
125. Telbisz A., Muller M., Ozvegy-Laczka C., Homolya L., Szente L., Varadi A., et al. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochimica et Biophysica Acta 2007, 1768:2698-2713.
126. Telbisz A., Ozvegy-Laczka C., Hegedus T., Varadi A., Sarkadi B. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. The Biochemical Journal 2013, 450:387-395.
127. Tieleman D.P., Maccallum J.L., Ash W.L., Kandt C., Xu Z., Monticelli L. Membrane protein simulations with a united-atom lipid and all-atom protein model: Lipid-protein interactions, side chain transfer free energies and model proteins. Journal of Physics. Condensed Matter: An Institute of Physics Journal 2006, 18:S1221-S1234.
128. Troost J., Lindenmaier H., Haefeli W.E., Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Molecular Pharmacology 2004, 66:1332-1339.
129. Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2010, 31:455-461.
130. Tusnady G.E., Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics 2001, 17:849-850.
131. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. The Journal of Biological Chemistry 1992, 267:24248-24252.
132. Urquhart B.L., Tirona R.G., Kim R.B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. Journal of Clinical Pharmacology 2007, 47:566-578.
133. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996, 87:507-517.
134. van Meer G., Voelker D.R., Feigenson G.W. Membrane lipids: Where they are and how they behave. Nature Reviews. Molecular Cell Biology 2008, 9:112-124.
135. Velamakanni S., Janvilisri T., Shahi S., van Veen H.W. A functional steroid-binding element in an ATP-binding cassette multidrug transporter. Molecular Pharmacology 2008, 73:12-17.
136. Wang H., LeCluyse E.L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clinical Pharmacokinetics 2003, 42:1331-1357.
137. Wang H., Lee E.W., Zhou L., Leung P.C., Ross D.D., Unadkat J.D., et al. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Molecular Pharmacology 2008, 73:845-854.
138. Wen P.C., Verhalen B., Wilkens S., McHaourab H.S., Tajkhorshid E. On the origin of large flexibility of P-glycoprotein in the inward-facing state. The Journal of Biological Chemistry 2013, 288:19211-19220.
139. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature 1998, 393:392-396.
140. Woodward O.M., Kottgen A., Coresh J., Boerwinkle E., Guggino W.B., Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:10338-10342.
141. Xu J., Liu Y., Yang Y., Bates S., Zhang J.T. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. The Journal of Biological Chemistry 2004, 279:19781-19789.
142. Zidovetzki R., Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: Evidence, misconceptions and control strategies. Biochimica et Biophysica Acta 2007, 1768:1311-1324.
143. Zordan-Nudo T., Ling V., Liu Z., Georges E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Research 1993, 53:5994-6000.